

PATENT

Attorney Docket No.: 00537/168002

PATENT APPLICATION
UNDER 37 CFR 1.53(B)

TITLE: GINKGOLIDES FOR INHIBITION OF MEMBRANE
EXPRESSION OF BENZODIAZEPINE
RECEPTORS

APPLICANT: KATY DRIEU

Express Mail Label No.: EL602065575US

09879306 061201

GINKGOLIDES FOR INHIBITION OF MEMBRANE EXPRESSION
OF BENZODIAZEPINE RECEPTORS

5 *2017* Field of the Invention

The invention relates to the inhibition of membrane expression of benzodiazepine receptors and in particular to the use of ginkgolides for the manufacture of medicaments for such membrane expression inhibition.

10

Background of the Invention

The steroid glucocorticoid is produced by adrenal fasciculata-reticula cells in the adrenal glands, and are secreted in response to an increase in the level of plasma adrenocorticotrophic hormone (ACTH).

15 Glucocorticoids are involved in carbohydrate, protein, and fat metabolism, have been shown to have anti-inflammatory properties, and are hypersecreted during stress. In excess, glucocorticoids have been shown to damage hippocampus, a structure in the limbic system of the brain that is critical to cognitive functions such as learning and memory. See, e.g., Sapolsky, R.M., Ann. N.Y. Acad. Sci. 746:294 (1994); and McEwen, B.S., Ann. N.Y. Acad. Sci. 746:134 (1994). Furthermore,

20 glucocorticoid neurotoxicity and neuroendangerment has been shown to be critical in neural development and aging as well as in neurological diseases related to hippocampal damage. See, e.g., deKloet, E.R., et al., Ann. N.Y. Acad. Sci. 746:8 (1994)

25 Studies have been conducted to examine the beneficial effects of extract of the leaves of the gymnospermus tree ginkgo biloba (e.g., EGb 761) on "antistress" activity by lowering corticosterone levels in stressed rat models. See, Rapin, et al., Gen. Pharmac. 25(5) :1009 (1994). EGb 761 had previously

30 been shown to have activity in the cardiovascular system (e.g., reduction of platelet adhesion and thrombi

35

09879306-061201

growth), central nervous system (e.g., neuroprotective activity), and neurosensory system (e.g., retinal protection). See, e.g., DeFeudis, et al., Ginkgo Biloba Extract (EGb 761): Pharmaceutical Activities and
5 Clinical Applications (Elsevier, Paris, 1991).

It has now been found that ginkgolides are effective at inhibiting membrane expression of benzodiazepine receptors, eg. adrenal benzodiazepine receptors, and that, having this effect, they can be
10 used to inhibit glucocorticoid release.

Summary of the Invention

Thus viewed from one aspect the invention provides the use of a ginkgolide for the manufacture of a
15 medicament for use as an inhibitor of membrane expression of a benzodiazepine receptor, eg. to inhibit glucocorticoid release in a patient. Alternatively viewed the invention provides the use of an inhibitor of membrane expression of an adrenal benzodiazepine
20 receptor, eg. a ginkgolide, for the manufacture of a medicament for inhibiting glucocorticoid release, eg. to combat (ie. prevent or treat) conditions associated with excess glucocorticoid production.

Viewed from a further aspect the invention provides
25 a pharmaceutical composition for use as an inhibitor of membrane expression of benzodiazepine receptors (or for combatting conditions associated with excess glucocorticoid production, etc.), said composition comprising a physiologically tolerable ginkgolide
30 together with at least one pharmaceutically acceptable carrier or excipient.

Viewed from a yet further aspect the invention provides a pharmaceutical composition for use as an inhibitor of glucocorticoid release, said composition
35 comprising an inhibitor of membrane expression of an adrenal benzodiazepine receptor (eg. a ginkgolide) together with at least one pharmaceutically acceptable

09879306 061201

carrier or excipient.

Viewed from a yet still further aspect the invention provides a method of inhibiting the membrane expression of a benzodiazepine receptor in a patient
5 (eg. a human or non-human, preferably a mammal), said method comprising administering to said patient an effective amount of a ginkgolide. Viewed from a still further aspect the invention provides a method of inhibiting the release of a glucocorticoid in a patient,
10 said method comprising administering to said patient an effective amount of a compound, eg. a ginkgolide, capable of inhibiting the membrane expression of an adrenal benzodiazepine receptor.

Reduction in excess glucocorticoid levels can, as
15 discussed below, result in enhancement of ACTH levels with various consequent beneficial effects.

Thus viewed from a still further aspect the invention also provides the use of a ginkgolide (or other inhibitor of membrane expression of an adrenal
20 benzodiazepine receptor) for the manufacture of a medicament for enhancing ACTH levels.

Thus one aspect of the invention involves inhibiting the membrane expression of a benzodiazepine receptor. This involves administering to a patient an
25 effective amount of a ginkgolide. The benzodiazepine receptor may be a peripheral-type benzodiazepine receptor (PBR), e.g. found on the adrenal, intestine, kidney, brain, liver, and testis. In one embodiment, the membrane is on adrenal mitochondria. In a further
30 embodiment, this method comprises administering an effective amount of an extract from ginkgo biloba. In another further embodiment this method comprises administering an effective amount of a pharmaceutical composition which contains a ginkgolide and a
35 pharmaceutically acceptable carrier.

However another aspect of the invention involves inhibiting the release of a glucocorticoid (such as

09879306-061201

09879306 061201

cortisol) in a patient. This involves the step of administering to the patient an effective amount of a compound capable of inhibiting the membrane expression of an adrenal benzodiazepine receptor. In one
5 embodiment, this method comprises administering to said patient an effective amount of a ginkgolide. In a further embodiment, this method comprises administering an effective amount of an extract from ginkgo biloba. In another further embodiment, this method comprises the
10 step of administering to the patient an effective amount of a pharmaceutical composition containing a ginkgolide and a pharmaceutically acceptable carrier.

An effective amount depends upon the condition being treated, the route of administration chosen, and
15 the specific activity of the compound used, and ultimately will be decided by the attending physician or veterinarian. The compound may be administered in an amount of 0.1 to 20 mg/kg body weight of the patient (e.g., 0.5 to 4 mg/kg body weight of the patient).

20 The pharmaceutical composition described above contains (1) one or more of the ginkgolides to be described below, (2) one or more pharmaceutically acceptable carriers, and, optionally, (3) one or more other ingredients such as another bioactive compound or
25 a stabilizing agent. Any extract from the ginkgo biloba tree is not considered as such a pharmaceutical composition. The carrier must be "pharmaceutically acceptable" in the sense of being compatible with the ginkgolide(s) of the composition and not deleterious to
30 the subject to be treated.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods
35 include the step of bringing the compound(s) (e.g., ginkgolide) into association with a carrier which may contain one or more accessory ingredients. In general, the compositions for tablets (e.g., for oral

administration) or powders are prepared by uniformly and intimately blending the compound(s) with finely divided solid carriers, and then, if necessary as in the case of tablets, forming the product into the desired shape and size.

Compositions suitable for parenteral administration (e.g., subcutaneous, intravenous, or intermuscular), on the other hand, conveniently comprise sterile aqueous solutions of the compound(s). Preferably, the solutions are isotonic with the blood of the subject to be treated. Such compositions may be conveniently prepared by dissolving solid compound(s) in water or saline to produce an aqueous solution, and rendering said solution sterile. The composition may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.

The extracts of the ginkgo biloba tree may be prepared by standard extraction techniques. See, e.g., the book, "Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives", edited by P. Braquet (J.R. Prous, Science Publishers, Barcelona, Spain 1988).

Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.

Detailed Description of the Invention

It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications

09879306-061201

cited herein are incorporated by reference.

Ginkgolides


5 The term "ginkgolide" are used herein to include
all the naturally occurring ginkgolides which are
derived from the ginkgo biloba tree as well as
synthetically produced ginkgolides and pharmaceutically
active derivatives and salts thereof. Thus, it includes
10 (1) the various ginkgolides disclosed in the books
"Ginkgolides - Chemistry, Biology, Pharmacology and
Clinical Perspectives", edited by P. Braquet (J.R.
Prous, Science Publishers, Barcelona, Spain 1988); F.V.
DeFeudis, Ginkgo Biloba Extract (EGb 761),
Pharmacological Activities and Chemical Applications
15 (Elsevier, Paris, France 1991); Rokan Ginkgo Biloba -
Recent Results in Pharmacology and Clinic, edited by
E.W. Feufgeld (Springer-Verlag, Berlin, Germany 1988)
and in U.S. Patent Nos. 4,734,280 and 5,002,965; and (2)
non-toxic, pharmaceutically active derivatives thereof
20 such as 2,3-dehydro, 1-methoxy, and 1-ethoxy derivatives
of ginkgolide B, tetrahydro ginkgolide derivatives,
acetyl ginkgolide derivatives, and alkyl ester of
ginkgolide, e.g., the monoacetate ginkgolide derivatives
described in Okabe, et al., J. Chem. Soc.(C) pp. 2201-
25 2206 (1967); and Corey, et al., J. Amer. Chem. Soc.
110:649 (1988).

As described in the book "Ginkgolides - Chemistry,
Biology, Pharmacology and Clinical Perspectives", pp.
27-42, edited by P. Braquet (J.R. Prous, Science
30 Publishers, Barcelona, Spain 1988), ginkgolides may be
extracted and purified from the leaves of the ginkgo
biloba tree. See, e.g., Okabe, J. Chem. Soc. (C) pp.
2201 (1967); and Nakanishi, Pure & Applied Chem. 14:89
(1967). Ginkgolides and ginkgolide derivatives have
35 also been chemically synthesized. See, e.g., Corey, et
al., J. Amer. Chem. Soc. 110:649 (1988). Furthermore,
ginkgolides are available from various commercial

09879306-061201

sources such as Sigma Chemical (St. Louis, Missouri, USA).

Structurally, ginkgolides are twenty carbon molecules with 6 five-membered rings joined together to form a constrained structure which incorporates a t-butyl group. Of the 6 rings, 3 are lactone rings, 2 are carboxylic rings joined by a single carbon to form a spiro-[4,4]nonane ring system, and 1 tetrahydrofuran ring. Examples of ginkgolides are depicted by the following formula:



wherein each of R^1 , R^2 , and R^3 , independently, is H, OH, or C_1-C_6 alkoxy, or a pharmaceutically acceptable salt thereof. Examples of ginkgolides include ginkgolide A ($R^1 = OH$, $R^2 = H$, $R^3 = H$), ginkgolide B ($R^1 = OH$, $R^2 = OH$, $R^3 = H$), ginkgolide C ($R^1 = OH$, $R^2 = OH$, $R^3 = OH$), ginkgolide J ($R^1 = OH$, $R^2 = H$, $R^3 = OH$), and ginkgolide M ($R^1 = H$, $R^2 = OH$, $R^3 = OH$) or the synthetic analogs where R^2 is C_1-C_6 alkoxy, e.g., 1-methoxy or 1-ethoxy derivatives of ginkgolide B. The term "ginkgolide" also includes all pharmaceutically acceptable salts of ginkgolides, such as sodium, potassium, and magnesium salts thereof. Examples of a ginkgolide to be used to practice the method of this invention has the above

09879306-061201

formula, in which each, R^1 and R^3 , independently, is H or OH, and R^2 is H, OH, or C_1-C_6 alkoxy (such as ginkgolides A, B, C, J, and M); or a pharmaceutically acceptable salt thereof.

5

Benzodiazepine Radioligand Binding Assay

10 The ginkgo biloba extract EGb761, ginkgolide A, and ginkgolide B (Institut Henri Beaufour-IPSEN, Paris, France) were tested for their ability to decrease the number of binding sites for the peripheral benzodiazepine receptor ligand PK 11195, which binds to an 18 Kd peripheral benzodiazepine receptor protein, in adrenal mitochondria. See, Garnier, et al., Endocrinology 132:444 (1993). Mitochondria were
15 prepared as described in Krueger, et al., J. Biol. Chem. 265:15015 (1990). Mitochondria (50 mg of protein) were resuspended in phosphate buffered saline (PBS) and [3H]PK 11195 (New England Nuclear, Wilmington, Delaware, USA). Binding studies were performed at 4°C in a final
20 incubation volume of 0.3 ml, using radioligand in the concentration range of 0.019-20.00 nM and 200 fold excess of unlabeled PK 11195 (Research Biochemicals, Natick, Massachusetts, USA), as described in Garnier, et al., Endocrinology 132:444 (1993) and Garnier, et al.,
25 Mol. Pharm. 45:201 (1994). After 120 min. incubation time, the assay was stopped by filtration through Whatman GF/C filters and washed with 15 ml ice-cold PBS. Radioactivity trapped on the filters were determined by liquid scintillation counting at 50% counting
30 efficiency. The dissociation constant (K_d) and the number of binding sites (B_{max}) were determined by Standard plot analysis of the data using the ligand™ program (Kell, V.4.0, Biosoft, Inc.). See Munson, et al., Anal. Biochem. 107:220 (1980). The results are
35 shown below in Table I.

09079306-061204

TABLE I

	Kd (nM)	Bmax (pmol/mg)
Control	1.7	11.2
EGb761	1.2	7.1
Ginkgolide A	1.3	5.6
Ginkgolide B	1.5	3.1

Thus, EGb761 decreased the expression of the 18 Kd peripheral benzodiazepine receptor protein by 40%, while ginkgolide A and ginkgolide B reduced the expression by 50% and 73%, respectively.

This finding was verified by immunocytochemical studies using antisera specific for the 18 Kd peripheral benzodiazepine receptor protein. See Oke, et al., Mol. Cell. Endocrinol. 87:R1 (1992) and Garnier, et al., Endocrinology 132:444 (1993). A dramatic decrease in the protein expression was observed after treatment with EGb761, ginkgolide A, and ginkgolide B.

Immunoblot Analysis of Benzodiazepine Receptor

The ginkgolide induced decrease in the 18 Kd peripheral benzodiazepine receptor protein was also confirmed by immunoblot analysis of mitochondrial extracts obtained from control and treated animals. Adrenal mitochondrial proteins were fractionated by one dimension SDS-PAGE and electro-transferred onto nitrocellulose as described in Oke, et al., Mol. Cell. Endocrinol. 87:R1 (1992) and Garnier, et al., Endocrinology 132:444 (1993). The nitrocellulose was subjected to immunoblot analysis using anti-peripheral benzodiazepine receptor antibody and goat IgG-horseradish peroxidase with 4-chloro-1-naphthol as color reagent and hydrogen peroxide as substrate. Densitometric analysis of the immunoreactivity protein bonds was performed using Sigmagel™ software (Jandel

09079306-061201

Scientific, San Rafael, California, USA). The densitometric analysis of the immunoreactivity found a 60% decrease of the 18 Kd peripheral benzodiazepine receptor protein by ginkgolide B.

5

mRNA Expression of Benzodiazepine Receptor

The ginkgolide induced decrease in mRNA expression of the benzodiazepine receptor was also confirmed. Total cellular RNA from adrenal tissue was isolated by the acid guanidinium thiocyanate-phenol-chloroform extraction method (Chomczynski, et al., Anal. Biochem. 162:156-159 (1987)) using the RNAzol B reagent (Tel-Test Inc., Friendswood, Texas, USA). RNA electrophoresis transfer, probe labelling, and membrane hybridization were performed as previously described in Dym, et al., Endocrinology 128:1167-1176 (1991). RNA was size-fractionated by electrophoresis and transferred to derivatized nylon membranes (Nytran Plus, Schleicher & Schuell, Keene, New Hampshire, USA). The blots were then hybridized against the [³²P]cDNA probe for PBR labelled by the random priming technique. The 781 base-pair probe for PBR mRNA used was prepared as previously described in Garnier, et al., Endocrinology 132:444-458 (1993). Screen enhanced autoradiography was performed by exposing Kodak X-OMAT AR films to the blots at -80°C for 48 hours. Densitometric analysis of the spots was performed as described above. Both EGb761 and ginkgolide B treatment was found to reduce peripheral benzodiazepine receptor mRNA expression by 50% and 85%, respectively.

Assay for Determining the Inhibition of Glucocorticoids

Adult Sprague-Dawley rats (approximately 300 g; Charles River Laboratories, Wilmington, Massachusetts, USA) were treated once daily for eight days with either ginkgolide A, ginkgolide B, or a saline control. Ginkgolide A and ginkgolide B were injected as an

09879306 "061201

aqueous solution intraperitoneally at a 2 mg/kg. The results shown in Table II are the means of between two to four independent experiments. In each experiment, at least six rats per treatment group were used. After eight days of treatment, the rats were sacrificed.

The level of steroids in the rats was measured by radioimmunoassay from organic extracts of the collected serum. The levels of corticosterone (a glucocorticoid in rats) and testosterone were measured by radioimmunoassay using antibodies from Endocrine Sciences (Tarlana, California, USA) under conditions described by the supplier. The level of plasma ACTH was measured by radioimmunoassay using the method of Crousos, et al., New Engl. J. Med. 310:622 (1984). The level of aldosterone was measured by radioimmunoassay using a kit from Diagnostics Products Corp. (Los Angeles, California, USA). The mean steroid levels for each of the four treatment groups are reported in Table II.

TABLE II

TREATMENT	CORTICOSTERONE ng/ml	ACTH pg/ml	ALDOSTERONE pg/ml	TESTOSTERONE ng/ml
Control	161	28.0	685	4.50
Ginkgolide A	66	103	638	4.75
Ginkgolide B	75	71.4	883	4.50

Ginkgolide A and ginkgolide B were all found to decrease the level of corticosterone in the rats. Because glucocorticoid secretion induced by the pituitary ACTH is modulated by a negative feedback system on the hypothalamus, the decrease in corticosteroid levels in the rats as a result of the administration of ginkgolide A and ginkgolide B will induce a corresponding increase in pituitary ACTH release and, consequently, plasma ACTH levels.

As shown in Table II, treatment with either ginkgolide A or ginkgolide B was found unexpectedly to cause the rats to naturally respond and increase ACTH release. Furthermore, serum levels of aldosterone (secreted by the adrenal cortex) and testosterone (secreted by the testes) were unaffected by the treatment of ginkgolide A and ginkgolide B, indicating that ginkgolides specifically affect the adrenal fasciculata-reticular cells of the adrenal gland.

Use

By inhibiting the release of glucocorticoids from the adrenal glands, ginkgolides can be used to treat disorders in patients that are secreting a high level of one or more glucocorticoids. Examples of such patients include those suffering from Cushing's syndrome and those with stress-induced hypercortisolism. As discussed above, the levels of ACTH are naturally elevated in response to the suppression of glucocorticoid release upon administration of a ginkgolide. Elevated levels of ACTH or ACTH analogs have been shown to inhibit brain aging (e.g., inhibit neurological loss and improve learning). See, e.g., Laudfield, et al., Science, 214:581 (1981). Thus, ginkgolides enhance brain function by both inhibiting glucocorticoid and maintaining normal ACTH release.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.